In the last trading session, 1,228,441 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) shares changed hands as the company’s beta touched 1.64. With the company’s per share price at $2.1 changed hands at -$0.12 or -0.05% during last session, the market valuation stood at $161.59 Million. CATB’s last price was a discount, traded about -309.05% off its 52-week high of $8.59. The share price had its 52-week low at $1.25, which suggests the last value was 40.48% up since then. When we look at Catabasis Pharmaceuticals, Inc.’s average trading volume, we note the 10-day average is 5.96 Million shares, with the 3-month average coming to 931.62 Million.
Analysts gave the Catabasis Pharmaceuticals, Inc. (CATB) stock a consensus recommendation rating of Overweight, calculated at a mean rating of 1.7. If we narrow down to specifics, the data shows that none out of 3 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, 1 recommended CATB as a Hold, 2 felt it is a Buy and none rated the stock as Underweight. Catabasis Pharmaceuticals, Inc.’s EPS for the current quarter is expected to be -$0.3.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) trade information
Although CATB has turned red as seen at the end of in last trading. With action -5.41%, the performance over the past five days has been green. The jump to weekly highs of $2.62- on Wednesday, Jun 16 added 19.85% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.02%, with the 5-day performance at 0.01% in the green. However, in the 30-day time frame, Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is 0.12% up. Looking at the short shares, we see there were 4.05 Million shares sold at short interest cover period of 0 days.
The consensus price target for the stock as assigned by Wall Street analysts is $5.5, meaning bulls need an upside of 161.9% from its current market value. According to analyst projections, CATB’s forecast low is $5 with $6 as the target high. To hit the forecast high, the stock’s price needs a +185.71% upsurge from its current level, while the stock would need to tank 138.1% for it to hit the projected low.
Catabasis Pharmaceuticals, Inc. (CATB) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 37.5%. The 2021 estimates are for Catabasis Pharmaceuticals, Inc. earnings to increase by 13.4%, but the outlook for the next 5-year period is at 0% per year.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.11% of Catabasis Pharmaceuticals, Inc. shares while 60.3% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 60.37%. There are 87 institutions holding the Catabasis Pharmaceuticals, Inc. stock share, with Perceptive Advisors Llc the top institutional holder. As of Mar 30, 2021, the company held 10.58% of the shares, roughly 2.48 Million CATB shares worth $7.16 Million.
Sphera Funds Management Ltd holds the second largest percentage of outstanding shares, with 5.53% or 1.29 Million shares worth $3.74 Million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 514051 shares estimated at $1.49 Million under it, the former controlled 2.2% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.91% of the shares, roughly 447.08 Thousand shares worth around $1.29 Million.